Adgero Biopharmaceuticals Holdings Inc. has appointed John Liatos as its chief financial officer.
The Princeton-based biopharmaceutical company’s focus is on its late-stage photodynamic therapy platform for the treatment of serious skin cancers.
“John is an excellent addition to our management team and joins Adgero at an exciting stage of the company as we work to advance our lead product candidate, REM-001 Therapy, towards late-stage clinical development and commercialization,” said Frank Pilkiewicz, chairman, CEO and president of Adgero. “I believe that his broad operational and financial expertise, combined with his strong business acumen, will be invaluable as we work towards continuing the successful execution of our corporate and clinical milestones.”
Liatos has more than 20 years of experience in operations, corporate finance, private equity and venture capital related to the life sciences industry.
He was a co-founding partner at Aceras BioMedical LLC, a health care-focused investment firm that formed and managed new companies to acquire and develop pre-commercial stage biomedical assets.
Liatos was responsible for the overall formation and business strategy of Aceras and its portfolio companies, as well as evaluating new investments.
He also was co-founder and CFO of Huxley Pharmaceuticals Inc. and Sherrington Phamaceuticals Inc., both Aceras portfolio companies. Huxley was acquired by BioMarin Pharmaceutical Inc., while Sherrington went to Sorrento Therapeutics Inc.
Liatos also served as CFO of life-sciences investment fund Paramount BioSciences LLC, where his experience included management recruitment, deal structuring and negotiations, investment valuation, financial reporting and corporate transactions, including mergers and acquisitions, private placements and self-registrations for the Paramount portfolio companies.
